Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They have to give shareholders a month notice. Shorts will have to cover. This will pop.
Yes. This is Huge
Immune Therapeutics Inc.; Cytocom Inc.Collaborating to develop Lodonal and IRT-101 for use against COVID-19; working with federal agencies to seek fast-track approval of Lodonal to prevent or treat high-risk groups who are infected; it has modulated immune system function by decreasing elevated inflammatory responses associated with HIV and H1N1 influenza
How high can this go??
If everybody did that, what would happen??
Their's not much shares left. If you smacked cfgn, he runs away.
I see you don't like this ticker. You should try $r.tard. no RSS there I hear. Gltu.
In @ 84
Here's the list. https://t.co/TViSgANCgL?amp=1
$VXLLF .1641 was one of 12 biotech companies that had a meeting with President Trump a few days ago. This one hasn't run yet. And recently filed a patent.
Might get a huge share of that multi-billion funding on the vaccine.
VXLLF - Vaxil Bio Ltd.
VAXIL APPLIES FOR CORONAVIRUS VACCINE PATENT UNDER ITS ANTI-INFECTIVE VACCINES PLATFORM AND PROVIDES UPDATE ON THE EXERCISE OF WARRANTS
By
Published: Mar 10, 2020 9:11 a.m. ET
SHARE
NESS-ZIONA, Israel, Mar 10, 2020 (GLOBE NEWSWIRE via COMTEX) -- Not for distribution by US newswire or in United States
NESS-ZIONA, Israel, March 10, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. ("Vaxil" or the "Company") (VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, announces that it has submitted a new patent application for its anti-infective vaccines platform as a result of our recently announced COVID19 candidate discovery.
Vaxil has applied for a US patent (U.S 62/987,310) on a coronavirus vaccine that is intended to provide broad patent protection for novel vaccines, pharmaceutical compositions and methods of treating and preventing an infectious disease as well as methods for producing a peptide vaccine against coronaviruses.
The Company also announces that since our recent press release dated March 4, 2020, a further, $221,000 ("Warrant Proceeds") has been received from the exercise of 2,210,000 warrants, having an exercise price of $0.10 per warrant, that were previously issued in January 2018 ()January 2018 Warrants"). Upon exercise of the warrants an additional 2,221,000 common shares of the Company will be issued.
ABOUT VAXIL
Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin(TM) successfully completed a Phase 1/2 clinical trial in multiple myeloma and received orphan drug status from the FDA and EMA. The company continues to develop ImMucin [tm] and is also developing a tuberculosis vaccine / treatment that has demonstrated promising preliminary results with further preclinical evaluation underway at a top US academic and research institution. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.
Vaxil exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. These signal peptide domains are identified by VaxHit(TM), Vaxil's proprietary bioinformatic approach. These SPs induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by "educating" or specifically activating the immune system to recognize and attack the affected cells. In addition, Vaxil's mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells.
Still under the radar. Should be trading in dollars.
$VXLLF 0.20 Scientists at Israel’s Institute for Biological Research are expected to announce in the coming days that they have completed development of a vaccine for the new coronavirus COVID-19.
https://www.haaretz.com/israel-news/.premium-israeli-research-center-to-announce-it-developed-coronavirus-vaccine-sources-say-1.8665074
Once them filings start dropping, they'll be buying back.
MJLB SECURITY DETAILS
Share Structure
Market Cap ?
215,410
03/03/2020
Authorized Shares
500,000,000
03/02/2020
Outstanding Shares
143,606,643
03/02/2020
Restricted
Not Available
Unrestricted
Not Available
Held at DTC
Not Available
Float
8,998,482
03/08/2017
Par Value
0.001
There's no dilution here. Share structure hasn't changed in months. Was just updated recently
Market Cap ?
244,131
02/04/2020
Authorized Shares
500,000,000
02/03/2020
Outstanding Shares
143,606,643
02/03/2020
Restricted
Not Available
Unrestricted
Not Available
Mm's playing games here
And buying too.
This has been brought back down by very little volume. This company has several products online http://ultrack.ca/en-US/
Current OS of only 143 million
Currently trading 0017 with revs of 4+ million. Severely undervalued
$MJLB
Thanks Ecomike
Provide the links to your claim.
$MJLB
3.8 Millions in revenue https://www.zoominfo.com/c/mjlb-design/410663039
Share Structure
Market Cap 01/14/2020
247,003
Authorized Shares 01/02/2020
500,000,000
Outstanding Shares 01/02/2020
143,606,643
Yup! This is a .03-.05 stock. $MJLB
Once them filings hit, they'll be here chasing. Great time to add at this level.
$MJLB 4.8 million revenues
https://www.zoominfo.com/c/ultrack-solutions/371106832
$MJLB .0021 4+ millions revs
Only 143m OS real products
http://ultrack.ca/en-US/
$MJLB .0021 4+millions rev
Only 143M OS real products
http://ultrack.ca/en-US/
MJLB .0021
4+ millions rev
Only 143mil os.
real company,
real products
Real company, real products
http://ultrack.ca/en-US/
We help our clients locate, track and manage their assets using todays leading edge wireless and GPS based technologies. This means we are able to provide an accurate and affordable means of tracking moving assets. Our compact trackers, and our easy to use tracking software allow us to monitor or track any asset virtually anywhere in the world. This kind of application results in improved security, productivity, and customer service that surpasses our competition. Monitor your driver's routes and location at all times. Streamline their paths to maximize driving time and fuel consumption. Each vehicle outfitted with a unit can be seen from our virtual map platform and managing a fleet of 10 or a 1000 vehicles becomes easy, efficient and effortless. This tool is useful in determining the quality of driver you have behind the wheel and who is an asset or a liability to the company.
Year end sale.$$$
We would like to announce our newest client and wish them all the success in their new venture https://pineappleexpressdelivery.com/
4.8 million revs and growing. New products being released every few months.
https://m.facebook.com/UltrackSolutions/
Real company, real products, great share structure.......$MJLB
Just took a 3rd of that small wall.
This is way undervalued. Multi-penny runner we got here. $MJLB
I like this stock. $MJLB